These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19669410)

  • 1. Statistical considerations for assessment of bioanalytical incurred sample reproducibility.
    Hoffman D
    AAPS J; 2009 Sep; 11(3):570-80. PubMed ID: 19669410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incurred Sample Reanalysis: Time to Change the Sample Size Calculation?
    Rudzki PJ; Biecek P; Kaza M
    AAPS J; 2019 Feb; 21(2):28. PubMed ID: 30746568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Workshop report and follow-up--AAPS Workshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples--implications of Crystal City recommendations.
    Fast DM; Kelley M; Viswanathan CT; O'Shaughnessy J; King SP; Chaudhary A; Weiner R; DeStefano AJ; Tang D
    AAPS J; 2009 Jun; 11(2):238-41. PubMed ID: 19381839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incurred sample reanalysis (ISR): a decisive tool in bioanalytical research.
    Yadav M; Shrivastav PS
    Bioanalysis; 2011 May; 3(9):1007-24. PubMed ID: 21545349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A decade of incurred sample reanalysis: failures, investigations and impact.
    Lee LB; Wickremsinhe ER
    Bioanalysis; 2018 Nov; 10(21):1767-1772. PubMed ID: 30301360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incurred sample reproducibility: 10 years of experiences: views and recommendations from the European Bioanalysis Forum.
    Kall MA; Michi M; van der Strate B; Freisleben A; Stoellner D; Timmerman P
    Bioanalysis; 2018 Nov; 10(21):1723-1732. PubMed ID: 30412676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmatory reanalysis of incurred bioanalytical samples.
    Rocci ML; Devanarayan V; Haughey DB; Jardieu P
    AAPS J; 2007 Oct; 9(3):E336-43. PubMed ID: 18170980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incurred sample reanalysis in AstraZeneca small molecule portfolio - what have we learned and where do we go next?
    Arfvidsson C; Wilson A; Heijer M; Bailey C; Severin P; Milligan F; Ngeny M; Dayton B; Li Y; Cape S
    Bioanalysis; 2018 Nov; 10(21):1733-1745. PubMed ID: 30325197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of imprecision in incurred sample reanalysis for small molecules.
    Subramaniam S; Patel D; Davit BM; Conner DP
    AAPS J; 2015 Jan; 17(1):206-15. PubMed ID: 25354732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A strategy for a post-method-validation use of incurred biological samples for establishing the acceptability of a liquid chromatography/tandem mass-spectrometric method for quantitation of drugs in biological samples.
    Jemal M; Ouyang Z; Powell ML
    Rapid Commun Mass Spectrom; 2002; 16(16):1538-47. PubMed ID: 12203245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incurred sample reanalysis at GSK: what have we learned?
    Summerfield SG; Barfield M; White SA
    Bioanalysis; 2018 Nov; 10(21):1755-1766. PubMed ID: 30325209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in validation, risk and uncertainty assessment of bioanalytical methods.
    Rozet E; Marini RD; Ziemons E; Boulanger B; Hubert P
    J Pharm Biomed Anal; 2011 Jun; 55(4):848-58. PubMed ID: 21237607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying trends and developing solutions for incurred sample reanalysis failure investigations in a bioanalytical CRO.
    Meng M; Reuschel S; Bennett P
    Bioanalysis; 2011 Feb; 3(4):449-65. PubMed ID: 21338264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of incurred sample reanalysis for macromolecules to evaluate bioanalytical method robustness: effects from imprecision.
    Thway TM; Eschenberg M; Calamba D; Macaraeg C; Ma M; DeSilva B
    AAPS J; 2011 Jun; 13(2):291-8. PubMed ID: 21461973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incurred sample reanalysis in drug discovery bioanalysis.
    Giri P; Patel N; Joshi V; Giri S; Srinivas NR
    Biomed Chromatogr; 2019 Mar; 33(3):e4430. PubMed ID: 30412644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations and perspectives on the practice of incurred sample reanalysis assessment for chiral drugs.
    Srinivas NR; Kallem RR; Bartlett MG
    Biomed Chromatogr; 2024 Sep; 38(9):e5954. PubMed ID: 38962861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incurred sample reanalysis: a global transformation.
    Viswanathan CT
    Bioanalysis; 2011 Dec; 3(23):2601-2. PubMed ID: 22136048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAPS and US FDA Crystal City VI workshop on bioanalytical method validation for biomarkers.
    Lowes S; Ackermann BL
    Bioanalysis; 2016 Feb; 8(3):163-7. PubMed ID: 26795584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Workshop Report: Crystal City VI-Bioanalytical Method Validation for Biomarkers.
    Arnold ME; Booth B; King L; Ray C
    AAPS J; 2016 Nov; 18(6):1366-1372. PubMed ID: 27514862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fit-for-Purpose Quality Control System in Continuous Bioanalysis During Long-Term Pediatric Studies.
    Ali M; Tins J; Burckhardt BB;
    AAPS J; 2019 Sep; 21(6):104. PubMed ID: 31485787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.